Renal Denervation Market to be Grow by 9.45% CAGR through 2030F
Increasing
cases of hypertension are expected to drive Global Renal Denervation Market in
the forecast period 2026-2030
According to TechSci Research report, “Renal
Denervation Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2020-2030F”, Global Renal Denervation Market was valued at USD 512.34 Million in 2024 and is expected to reach USD 873.85 Million by 2030 with a CAGR of 9.45% during the forecast period. This
can be ascribed to the increasing chronic diseases such as diabetes and
obesity, rising prevalence of hypertension, and growing demand for treatment of
hypertension along with rising preference of healthcare providers towards
minimally invasive procedures for the treatment of resistant hypertension are
further expected to increase the demand for Renal Denervation Market in the
forecast period. Similarly, an increase in the number of people who smoke and
drink alcohol, sedentary and hectic lifestyles, increasing unhealthy dietary
patterns, and increasing focus on research and development to develop novel
products are expected to become part of the Global Renal Denervation Market
during the forecast period due to the adverse effects on such consumptions.
However, the risk of infection that can cause after
surgery, the high cost of these techniques, and lack of awareness among people
and healthcare providers about new technique is the main factor that will
hamper The Global Renal Denervation Market in the forecast period.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Renal Denervation Market"
The global renal denervation market
is segmented based on technology, product, therapeutic area, end user and by
region.
Based on therapeutic area, Hypertension is the fastest-growing condition segment driving demand in the global renal denervation market, as the procedure is specifically designed to address resistant hypertension—high blood pressure that remains uncontrolled despite multiple antihypertensive medications. Affecting over 1.28 billion people globally (according to WHO), hypertension poses a major public health challenge, particularly as a significant portion of patients either fail to respond to conventional drug therapies or suffer from side effects. Renal denervation presents a groundbreaking, non-pharmacologic, and minimally invasive alternative by targeting overactive renal sympathetic nerves, which play a key role in sustaining elevated blood pressure. This targeted approach has gained rapid traction, with increasing clinical validation, growing regulatory approvals, and physician confidence fueling widespread adoption. Although other conditions such as heart failure, diabetes, and renal impairment are closely linked to hypertension and may indirectly benefit from improved blood pressure control, they remain secondary indications for renal denervation. The strongest clinical evidence, highest commercial interest, and most immediate patient need all converge around hypertension—making it the clear driver of market growth. With resistant hypertension on the rise and demand for drug-free, durable interventions increasing, hypertension continues to be the fastest-growing and most strategically important segment in the renal denervation space.
Based on Region, the Asia-Pacific is the fastest-growing region in the global renal
denervation market due to a combination of rising hypertension prevalence,
expanding healthcare infrastructure, and increasing adoption of advanced
medical technologies. The region is experiencing rapid urbanization, aging
populations, and lifestyle shifts, all of which contribute to a surge in
hypertension cases. Countries like China, India, and Japan report high rates of
both diagnosed and undiagnosed hypertension, creating a substantial patient
base for alternative treatment options like renal denervation. Governments
across Asia-Pacific are increasing investments in healthcare systems, making
advanced interventional procedures more accessible. As awareness of the
limitations of drug-based hypertension management grows, both physicians and
patients are seeking more effective, long-term solutions. The presence of local
clinical trials and partnerships with global medtech companies is accelerating
the introduction and acceptance of renal denervation technology. Medical
tourism, particularly in countries such as India and Thailand, also supports
procedural demand by attracting international patients. The increasing
physician training, greater focus on non-communicable disease control, and
favorable regulatory pathways are contributing to the region’s growth. With a
large hypertensive population and evolving healthcare capabilities,
Asia-Pacific presents a highly attractive environment for renal denervation
adoption and is expected to play a key role in future market expansion.
Major companies operating in global
renal denervation market are:
·
Medtronic Plc.
·
Boston Scientific Corporation
·
Abbott Laboratories, Inc.
·
Terumo Corporation
·
Johnson & Johnson
·
Cordis Corporation
·
ReCor Medical, Inc. (Otsuka Holdings)
·
Cardiosonic Ltd
·
Mercator MedSystems, Inc
·
Renal Dynamics Limited
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The global renal denervation market is experiencing
strong growth due to rising cases of resistant hypertension, advancements in
ablation technologies, and increasing demand for non-drug treatment options.
Supportive clinical trial outcomes, regulatory approvals, and expanding
healthcare infrastructure are driving adoption. Growing awareness among
physicians and patients, combined with improved reimbursement frameworks, is
further accelerating market expansion, particularly in emerging regions such as
Asia-Pacific and Latin America”, said Mr. Karan Chechi, Research Director of TechSci Research, a research based global management consulting firm.
“Renal Denervation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Technology (Ultrasound Ablation, Radiofrequency Ablation, Pharmacologic Ablation, and Microinfusion), By Product (Catheters, Single Electrode Catheter, Multi Electrode Catheter, RF Generator, and Others), By Therapeutic Area (Hypertension, Heart Failure, Diabetes, Renal Failure, and Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, and Others), By Region and Competition, 2020-2030F”, has
evaluated the future growth potential of global renal denervation market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in global renal denervation market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com